AEROVATE THERAPEUTICS INC's ticker is AVTE and the CUSIP is 008064107. A total of 64 filers reported holding AEROVATE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $6,884 | -88.7% | 4,147 | +101.3% | 0.00% | -100.0% |
| Q1 2024 | $60,914 | +191.9% | 2,060 | +123.4% | 0.00% | – |
| Q4 2023 | $20,865 | +6.8% | 922 | -36.0% | 0.00% | -100.0% |
| Q3 2023 | $19,541 | +25.5% | 1,440 | +58.6% | 0.00% | 0.0% |
| Q2 2023 | $15,572 | +28212.7% | 908 | -66.4% | 0.00% | -50.0% |
| Q1 2023 | $55 | +61.8% | 2,702 | +136.2% | 0.00% | +100.0% |
| Q4 2022 | $34 | -99.9% | 1,144 | -66.8% | 0.00% | 0.0% |
| Q3 2022 | $57,000 | +612.5% | 3,449 | +569.7% | 0.00% | – |
| Q2 2022 | $8,000 | -69.2% | 515 | -63.7% | 0.00% | – |
| Q1 2022 | $26,000 | -29.7% | 1,418 | -54.6% | 0.00% | -100.0% |
| Q4 2021 | $37,000 | +311.1% | 3,124 | +654.6% | 0.00% | – |
| Q3 2021 | $9,000 | +80.0% | 414 | +76.2% | 0.00% | – |
| Q2 2021 | $5,000 | – | 235 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| OUP Management Co., LLC | 603,762 | $8,193,050 | 18.42% |
| TCG Crossover Management, LLC | 2,201,274 | $29,871,288 | 4.40% |
| Atlas Venture Life Science Advisors, LLC | 2,039,249 | $27,672,609 | 4.29% |
| Sofinnova Investments, Inc. | 3,758,686 | $51,005,369 | 3.22% |
| GREAT POINT PARTNERS LLC | 1,091,233 | $14,808,032 | 2.70% |
| RA Capital Management | 8,263,982 | $112,142,236 | 2.21% |
| Cormorant Asset Management, LP | 1,561,696 | $21,192,215 | 1.24% |
| Frazier Life Sciences Management, L.P. | 1,204,867 | $16,350,045 | 1.09% |
| Octagon Capital Advisors LP | 497,370 | $6,749,311 | 1.04% |
| Ghost Tree Capital, LLC | 201,197 | $2,730,243 | 0.90% |